KalVista Pharmaceuticals Inc

Venrock’s $95 million sale of 5 M KalVista shares highlights a potential valuation shift—why the move matters for investors and the company’s future.

Insider selling at KalVista shows routine trades, not a red flag—investors see solid fundamentals and growth potential in EKTERLY.

CEO buy of 15,625 KalVista shares signals cautious optimism for its protease‑inhibitor pipeline, offering a subtle positive cue for value‑oriented investors.

KalVista insider buys: CDO Yea Christopher’s RSU‑triggered purchase of 1,774 shares signals confidence amid EKTERLY data hype, offering a cautious buy hint for investors.

CEO’s insider RSU buy at KalVista signals long‑term confidence as EKTERLY data rises, hinting a potential biotech turnaround for value‑oriented investors.

KalVista CEO’s new share purchase signals confidence in the company’s EKTERLY pipeline and could hint at future upside for investors.